Enfortumab vedotin is an antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link.
- Mechanism
- Curator reviewed · 3 references
Enfortumab vedotin is an antibody-drug conjugate comprised of multiple components. It contains a fully human monoclonal antibody directed against Nectin-4, an extracellular adhesion protein which is highly expressed in urothelial cancers, attached to a chemotherapeutic microtubule-disrupting agent, monomethyl auristatin E (MMAE). These two components are joined via a protease-cleavable linker. Enfortumab vedotin binds to cells expressing Nectin-4 and the resulting enfortumab-Nectin-4 complex is internalized into the cell. Once inside the cell, MMAE is released from enfortumab vedotin via proteolytic cleavage and goes on to disrupt the microtubule network within the cell, arresting the cell cycle and ultimately inducing apoptosis.
- Primary indication
- Enfortumab vedotin is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and platinum-containing chemotherapy...Curator reviewed · 8 structured indications
- Formula / weight
- 152000.0 Da
- First approval
- Canada, 2025 · United States, 2019 · European Union, 2022
- Also known as
- enfortumab vedotin-ejfv
- Code names
- AGS-22M6E · AGS-22ME · ASG-22CE
- Brand names
Resolves to
What you can answer from here — as of September 25, 2026
Which drugs share a target with Enfortumab vedotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account